All Eyes on Cel-Sci: Will Wednesday's Surge Continue?

Dec.10.09 | About: Cel-Sci Corporation (CVM)

With a late day surge of nearly twenty cents on Wednesday, Cel-Sci (NYSEMKT:CVM) will be a stock to watch during Thursday's trading. Investors will be looking for indications of whether or not the move was for real, and marking the end of the recent downtrend.

With a late day surge like the one CVM enjoyed, it's possible that news is brewing and a PR is pending, but it's also possible that it could just be another head fake, possibly the result of manipulation, and the stock will continue to trade down for the short term.

In my opinion, the volume that accompanied the late surge would indicate that the spike was more than just a fluke.

As followers of Cel Sci know, news should be imminent regarding the validation of the Baltimore area Multikine production facility, which should be shortly followed by an announcement that the long awaited Multikine Phase III trial has commenced. For those that may be new to Cel Sci, Multikine is the company's head and neck cancer immunotherapy treatment.

An update from the LEAPS H1N1 trial at Johns Hopkins could also come at any time, and if positive, the CVM stock should respond accordingly.

On a lesser note, the website 'Motley Fool' released a late day article that gave CVM a mention, but it's likely that the Fool was just playing the 'search for clicks game (a la' with a popular stock because the article had little relevance to Cel Sci or its stock.

Anticipation is growing for shareholders of CVM, and Wednesday's late day surge only adds to the excitement.

Therefore, CVM is a stock to watch for Thursday.

Disclosure: VFC is long CVM.